# Solarea Bio

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/solarea-bio

- Industry: Biotechnology
- Headquarters: Cambridge, US
- Website: www.solareabio.com
- Total disclosed funding: $26M
- Latest round: Series B (May 3, 2023)
- Investors on record: 7

## About

Based in the US, Solarea Bio, Inc. operates as a biotechnology firm focusing on developing all-natural solutions for age-related inflammatory conditions utilizing proprietary Microscape Technology™.Solarea Bio, Inc. specializes in creating innovative health solutions. Founded in 2017 in Cambridge, US, the company has executed 3 deals, with its most recent funding round occurring on May 3, 2023. The latest funding round, Series B, raised USD 15.00 mn, with investments from S2G Ventures, Bold Capital Partners, GG 1978 SICAF SIF S.A., and Viking Global Investors. The total amount raised by Solarea Bio is USD 15.00 mn, with a current company valuation of USD 41.23 mn. The CEO and Founder is Gerardo Toledo, who has a background in health-focused innovation.Solarea Bio specializes in developing all-natural solutions aimed at addressing age-related inflammatory conditions through their proprietary Microscape Technology™. This technology isolates beneficial bacteria and fungi found in fruits and vegetables, which are integrated into their product line. Their offerings include formulations designed to support individuals with rheumatoid arthritis, psoriatic arthritis, and cellular aging, specifically targeting clinically validated benefits such as slowing bone loss, with studies pending peer review and publication. The company's products are aimed at health-conscious consumers in North America and select international markets, focusing on microbiome-based dietary solutions.Solarea Bio generates revenue through direct-to-consumer sales complemented by partnerships with healthcare providers and retailers in the health and wellness sector. The company allows customers to purchase its flagship products that leverage Microscape Technology™ for specific health concerns. While specific pricing plans for individual products are undisclosed, Solarea positions itself within the premium market segment, reflecting the specialized nature of its offerings and reinforces its commitment to unlocking novel microbial solutions.In May 2023, Solarea Bio, Inc. raised USD 15.00 mn in Series B funding, led by S2G Ventures and supported by other investors, to support the commercial launch of its two new medical food products. The company aims to expand into various markets, further enhancing its reach within North America and select international regions. This funding will enable Solarea to advance its product development and strengthen its market presence.

## Funding rounds

- Series B, May 3, 2023, $15M — Viking Global Investors, S2G Ventures, BOLD Capital Partners, GG 1978 SICAF SIF S.A.
- Series A, Aug 31, 2020, $11M — Viking Global Investors, S2G Ventures, BOLD Capital Partners, Gisev Family Office
- Seed, Jul 17, 2018 — Social Starts, Rising Tide

## Investors

- Social Starts (https://capitalatlas.ai/funds/social-starts) — Seed
- Rising Tide — Seed
- Viking Global Investors (https://capitalatlas.ai/funds/viking-global-investors) — Series A, Series B
- S2G Ventures (https://capitalatlas.ai/funds/s2g-ventures) — Series A, Series B
- BOLD Capital Partners (https://capitalatlas.ai/funds/bold-capital-partners) — Series A, Series B
- Gisev Family Office — Series A
- GG 1978 SICAF SIF S.A. — Series B